Bevacizumab-based therapy for advanced small bowel adenocarcinoma.
Tsang
H
H
Yau
T
T
Khong
P L
PL
Epstein
R J
RJ
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D007421:Intestine, Small; D053773:Transforming Growth Factor beta1 / Q000378:metabolism; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053773:Transforming Growth Factor beta1; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab